The “Obesity – Pipeline Insight, 2021” drug pipeline has been added to ResearchAndMarkets.com’s offering.
This “Obesity – Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.
Obesity Emerging Drugs Chapters
This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obesity Emerging Drugs
Tirzepatide: Eli Lilly and Company
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, therefore, resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in the phase 3 stage of development for the treatment of obesity.
Danuglipron: Pfizer
Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in the phase 2 stage of development for the treatment of obesity.
Noiiglutide: Jiangsu Hansoh Pharmaceutical
Noiiglutide is a glucagon-like peptide-1 (GLP-1) analog being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in the phase 2 stage of development.
MEDI 0382: MedImmune
MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1 and glucagon receptor activity. MEDI0382 was discovered and developed in MedImmune’s labs and is a dual agonist using natural amino acids. Currently, it is in the phase 2 stage of development for the treatment of obesity.
Obesity: Therapeutic Assessment
This segment of the report provides insights about the different Obesity drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Obesity
There are approx. 50+ key companies are developing therapies for Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. phase III include, Eli Lilly and Company.
Source: Businesswire
